Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAYRY Bayer Aktiengesellschaft	$7.95 +4.3%	$6.57	$4.79 ▼ $8.58	$31.24B	0.85	814,784 shs	640,858 shs
BMY Bristol-Myers Squibb	$50.13 +0.3%	$48.87	$39.35 ▼ $63.33	$102.01B	0.38	12.98 million shs	10.97 million shs
GSK GSK	$41.59 +0.7%	$37.81	$31.72 ▼ $44.67	$85.23B	0.52	4.82 million shs	4.49 million shs
VRTX Vertex Pharmaceuticals	$452.44 +0.2%	$463.17	$377.85 ▼ $519.88	$116.19B	0.41	1.41 million shs	1.02 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAYRY Bayer Aktiengesellschaft	+4.33%	+10.26%	+17.95%	+27.61%	+8.94%
BMY Bristol-Myers Squibb	+0.35%	+4.41%	+4.18%	-16.76%	+16.47%
GSK GSK	+0.69%	+1.85%	+11.36%	+5.99%	+1.35%
VRTX Vertex Pharmaceuticals	+0.20%	+1.48%	+2.97%	-10.04%	-6.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BAYRY Bayer Aktiengesellschaft	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BMY Bristol-Myers Squibb	4.7746 of 5 stars	3.2	4.0	4.2	4.0	2.8	3.3	0.0
GSK GSK	1.7006 of 5 stars	1.1	4.0	2.5	0.0	2.2	0.0	1.9
VRTX Vertex Pharmaceuticals	4.5519 of 5 stars	3.3	5.0	0.0	3.3	2.4	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BAYRY Bayer Aktiengesellschaft	2.75	Moderate Buy	N/A	N/A
BMY Bristol-Myers Squibb	2.32	Hold	$58.00	15.70% Upside
GSK GSK	2.27	Hold	$37.38	-10.12% Downside
VRTX Vertex Pharmaceuticals	2.57	Moderate Buy	$515.04	13.84% Upside

Current Analyst Ratings Breakdown

Latest BAYRY, VRTX, BMY, and GSK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	BAYRY Bayer Aktiengesellschaft	Kepler Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
6/5/2025	BAYRY Bayer Aktiengesellschaft	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/3/2025	GSK GSK	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/23/2025	VRTX Vertex Pharmaceuticals	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/7/2025	VRTX Vertex Pharmaceuticals	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
5/6/2025	VRTX Vertex Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/6/2025	VRTX Vertex Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/6/2025	VRTX Vertex Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/6/2025	VRTX Vertex Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$450.00 ➝ $442.00
5/6/2025	VRTX Vertex Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$420.00 ➝ $423.00
5/6/2025	VRTX Vertex Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$462.00 ➝ $464.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BAYRY Bayer Aktiengesellschaft	$51.55B	0.61	$6.21 per share	1.28	$9.11 per share	0.87
BMY Bristol-Myers Squibb	$47.64B	2.14	$5.29 per share	9.48	$8.08 per share	6.20
GSK GSK	$31.53B	2.70	$6.58 per share	6.32	$8.07 per share	5.15
VRTX Vertex Pharmaceuticals	$11.10B	10.47	N/A	N/A	$63.90 per share	7.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BAYRY Bayer Aktiengesellschaft	-$3.18B	-$0.92	N/A	6.97	N/A	-2.02%	16.90%	4.94%	8/5/2025 (Estimated)
BMY Bristol-Myers Squibb	-$8.95B	$2.67	N/A	8.23	2.07	-18.53%	13.93%	2.46%	7/25/2025 (Estimated)
GSK GSK	$3.29B	$1.94	26.15	8.94	1.12	8.13%	48.59%	11.11%	7/30/2025 (Estimated)
VRTX Vertex Pharmaceuticals	-$535.60M	-$3.92	N/A	25.84	2.11	-4.86%	-2.02%	-1.49%	7/30/2025 (Estimated)

Latest BAYRY, VRTX, BMY, and GSK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	BAYRY Bayer Aktiengesellschaft	$0.63	$0.65	+$0.02	$0.35	$13.39 billion	$15.27 billion
5/5/2025	Q1 2025	VRTX Vertex Pharmaceuticals	$4.29	$4.06	-$0.23	$2.49	$2.85 billion	$2.77 billion
4/30/2025	Q1 2025	GSK GSK	$1.08	$1.13	+$0.05	$1.00	$7.52 billion	$10.06 billion
4/24/2025	Q1 2025	BMY Bristol-Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BAYRY Bayer Aktiengesellschaft	$0.02	0.25%	N/A	N/A	N/A
BMY Bristol-Myers Squibb	$2.48	4.95%	N/A	92.88%	17 Years
GSK GSK	$1.68	4.04%	N/A	86.60%	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest BAYRY, VRTX, BMY, and GSK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	GSK GSK	quarterly	$0.4216	4.1%	5/16/2025	5/16/2025	7/10/2025
4/22/2025	BAYRY Bayer Aktiengesellschaft		$0.0224	0.38%	4/29/2025	4/30/2025	5/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BAYRY Bayer Aktiengesellschaft	1.19	1.32	0.81
BMY Bristol-Myers Squibb	2.90	1.25	1.15
GSK GSK	1.12	0.78	0.52
VRTX Vertex Pharmaceuticals	0.01	2.69	2.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BAYRY Bayer Aktiengesellschaft	N/A
BMY Bristol-Myers Squibb	76.41%
GSK GSK	15.74%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
BAYRY Bayer Aktiengesellschaft	N/A
BMY Bristol-Myers Squibb	0.09%
GSK GSK	10.00%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BAYRY Bayer Aktiengesellschaft	99,723	3.93 billion	N/A	Not Optionable
BMY Bristol-Myers Squibb	34,300	2.04 billion	2.03 billion	Optionable
GSK GSK	90,100	2.05 billion	1.87 billion	Optionable
VRTX Vertex Pharmaceuticals	4,800	256.80 million	256.28 million	Optionable

BAYRY, VRTX, BMY, and GSK Headlines

Recent News About These Companies

Greenwood Capital Associates LLC Sells 6,572 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 12 at 7:33 AM | marketbeat.com

Simon Quick Advisors LLC Has $1.42 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 12 at 7:02 AM | marketbeat.com

SG Americas Securities LLC Raises Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 12 at 5:26 AM | marketbeat.com

Simplicity Wealth LLC Acquires 581 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 12 at 5:03 AM | marketbeat.com

Vertex to lay off 125 employees in R.I., consolidate offices

June 12 at 3:40 AM | bostonglobe.com

Cantor Fitzgerald Weighs in on VRTX FY2026 Earnings

June 12 at 1:45 AM | americanbankingnews.com

Vertex Presents New Data on the Benefits of ALYFTREK

June 11 at 9:25 PM | insidermonkey.com

Equities Analysts Issue Forecasts for VRTX FY2026 Earnings

June 11 at 8:45 AM | marketbeat.com

Redhawk Wealth Advisors Inc. Sells 655 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 11 at 7:14 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Position Reduced by Assenagon Asset Management S.A.

June 11 at 6:54 AM | marketbeat.com

Yousif Capital Management LLC Sells 664 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 11 at 5:26 AM | marketbeat.com

UPDATED: Vertex Pharmaceuticals to Lay Off 125 in Rhode Island

June 11 at 3:42 AM | golocalprov.com

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

June 10 at 7:04 PM | seekingalpha.com

Handelsbanken Fonder AB Sells 88,391 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 10 at 8:28 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Avanza Fonder AB

June 10 at 7:38 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Parsons Capital Management Inc. RI

June 10 at 7:29 AM | marketbeat.com

First National Bank of Mount Dora Trust Investment Services Sells 4,882 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 10 at 7:27 AM | marketbeat.com

1 Nasdaq 100 Stock for Long-Term Investors and 2 to Ignore

June 10 at 7:25 AM | msn.com

First Citizens Bank & Trust Co. Sells 639 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 10 at 4:49 AM | marketbeat.com

UMB Bank n.a. Reduces Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 10 at 4:19 AM | marketbeat.com

Portside Wealth Group LLC Boosts Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 9 at 7:43 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BAYRY, VRTX, BMY, and GSK Company Descriptions

Bayer Aktiengesellschaft OTCMKTS:BAYRY

$7.95 +0.33 (+4.33%)

As of 06/11/2025 03:59 PM Eastern

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Bristol-Myers Squibb NYSE:BMY

$50.13 +0.16 (+0.32%)

Closing price 06/11/2025 03:59 PM Eastern

Extended Trading

$49.88 -0.24 (-0.48%)

As of 07:18 AM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

GSK NYSE:GSK

$41.58 +0.29 (+0.69%)

Closing price 06/11/2025 03:59 PM Eastern

Extended Trading

$42.10 +0.52 (+1.24%)

As of 07:31 AM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Vertex Pharmaceuticals NASDAQ:VRTX

$452.44 +0.92 (+0.20%)

Closing price 06/11/2025 04:00 PM Eastern

Extended Trading

$452.44 0.00 (0.00%)

As of 07:30 AM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time